(P-1606) Clearance of Infectious Virus in COVID-19 Patients Treated with Ensitrelvir Across Vaccination Status, Age, and Risk Subgroups: Exploratory Analyses from the SCORPIO-HR Study

Wednesday, October 22, 2025

12:15 PM - 1:30 PM US ET

Location: Poster Hall B4-B5

Presenting Author(s)

Florin Draica, MD, CMD, MBA (he/him/his)

Vice President, US Medical Affairs
Medical Affairs, Shionogi, Inc., Florham Park, NJ, USA
Florham Park, NJ, United States

Annie Luetkemeyer, MD (she/her/hers)

Professor of Medicine
University of California San Francisco
San Francisco, CA, United States
Kara W. Chew, M.D., M.S.

Associate Professor
David Geffen School of Medicine at University of California
Los Angeles, California, United States
Judith S. Currier, MD, MSc (she/her/hers)

Professor of Medicine/ Executive Vice Chair for Research
David Geffen School of Medicine at University of California
Los Angeles, CA, United States
DS

David Smith, MD, MAS

Professor of Medicine
University of California, San Diego
San Diego, California, United States
SP

Simon Portsmouth, MD

Senior Medical Director
Shionogi Inc
Florham Park, NJ, United States
AH

Aeron C. Hurt, Ph.D.

Clinical Development, Shionogi & Co., Ltd., London, England, UK
London, England, United Kingdom
TH

Takahiro Hasegawa, DrPH

SHIONOGI & CO., LTD.
Osaka-shi, Osaka, Japan
SK

Safwan Kezbor, M.D.

Clinical Development, Shionogi Inc., Florham Park, NJ, USA
Florham Park, New Jersey, United States
DV

Daniel Verdi, M.D.

Medical Affairs, Shionogi, Inc., Florham Park, NJ, USA
Florham Park, New Jersey, United States
TU

Takeki Uehara, Ph.D.

SHIONOGI & CO., LTD.
Osaka-shi, Osaka, Japan